pros and cons of new hcv ttt
DESCRIPTION
New prospective, for HCV TherapyTRANSCRIPT
![Page 1: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/1.jpg)
Changing Concepts in HCV Therapy
( Pros and Cons )
Hosny Salama, MD( Cairo University )
Alex Hept. August, 21st, 2014
![Page 2: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/2.jpg)
ARE WE APPROACHING THE ERA OF
INTERFERON- FREE REGEMINS
![Page 3: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/3.jpg)
The Standard of Care Therapy for HCV
Depends upon giving PegIFN / Ribavirin for
24-48 Wks depending upon the Genotype
![Page 4: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/4.jpg)
Both drugs depends mainly in their effect upon
Boosting the Host immune response to control
and eradicate the HCV Infection
![Page 5: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/5.jpg)
The newly developed Directly Acting Antivirals –
DAAs - acts only at the virus Level with no effect
on the host immune system i.e the host immunity
is passive during these new lines of therapy .
![Page 6: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/6.jpg)
So, we are shifting from the host immune system
manipulation Towards virus body manipulation.
NB : The virus is a living organism and has to
defend its life through
? Resistance? Mutation ? etc
Like Antibiotics with Bacteria .
![Page 7: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/7.jpg)
So , do we need to Combine both modalities in the future Therapy ?
i. e. To have a Whiff of Interferon at the
beginning of therapy with DAAs to boost the host
immune system and this may Decrease the relapse
rate, break-though and resistance
( <<<<< We need more studies >>>>>)
![Page 8: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/8.jpg)
The advent of direct-acting antivirals- DAAs
Has revolutionized hepatitis C treatment .
![Page 9: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/9.jpg)
The First Protease Inhibitor that was tried in 2004 and was known as PILN 2061 and gave
100% eradication rate after 4 weeks only .
At that time it was considered a real revolution…..
However at 16 weeks all patients got cardiac toxicity and the trial was aborted
( Nature 2004 )
![Page 10: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/10.jpg)
The Real start of DAAa was Nov. 2011
FDA : PROTEASE INHIBITORS (NS-3 , 4A) 1st generation
Telaprevir ( Incivek )
Boceprevir ( Vectrelis )
![Page 11: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/11.jpg)
ADVANTAGES OF 1ST GEN. P. I
-INCREASED SVR RATE ( FROM 45 % TO 74% IN G 1A, 1B)
- DECREASED RELAPSE RATE ( FROM 12% TO 4% )
![Page 12: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/12.jpg)
DRAWBACKS OF 1ST GEN. P. I
* HIGHER COST* FREQUENT SIDE EFFECTS* HIGH DRUG DOSES ( 12-16 TABLs/D)* FREQUENT DRUG DISCONTINUTY ( 12% IN SOC # 49% IN TRIPLE TTT)* INTERFERON DEPENDANT* GENOTYPE SPECIFIC..G1 ONLY
![Page 13: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/13.jpg)
PROTEASE AND POLYMERASE
INHIBITORS : 2ND GENERATION
<< INTERFERON FREE REGIMENS >>
![Page 14: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/14.jpg)
DURING THE 62ND ANNUAL MEETING
OF AASLD, 2011
NEW HCV DRUG ACHIEVES 100% CURE RATE
WITHOUT INTERFERON
![Page 15: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/15.jpg)
IN ELECTRON — 1 OF 2 PHASE 2 STUDIES OF THE INVESTIGATIONAL COMPOUND
PSI-7977 (PHARMASSET) REPORTED HERE — AN INTERFERON-FREE REGIMEN OF PSI-7977 PLUS RIBAVIRIN ACHIEVED A 100% SUSTAINED VIRAL RESPONSE (SVR) AT 12 WEEKS IN ALL STUDY SUBJECTS.
![Page 16: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/16.jpg)
IN 2012 : Innovative Trial ::::
* SOFOSBUVIR ( NS5B INH.- GILEAD ) +
* DACLATASVIR (NS5A INH. BMS )
95% SVR
![Page 17: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/17.jpg)
GILEAD .. 2013
* SOFOSBUVIR ( NS5B INH. GILEAD )
* LEDIPASVIR ( NS5A INH. GILEAD )
(COMBO)
95% SVR INCREASED TO 100% WITH RIBAVIRIN
![Page 18: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/18.jpg)
BMS : 2013
* DACLATASVIR ( NS5A- BMS )+
* ASUNAPREVIR ( PI. BMS )
![Page 19: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/19.jpg)
BMS : A COMBINATION THERAPY INCLUDING TWO DIRECT-ACTING ANTIVIRAL AGENTS (DAAS)
ASUNAPREVIR AND DACLATASVIR
SUPPRESSED HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION IN A 93% OF PATIENTS WHO HAD PREVIOUSLY NOT RESPONDED TO TREATMENT .
![Page 20: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/20.jpg)
IN Nov. 22ND 2013 ::: FDA APPROVAL FOR
- POLYMERASE INHIBITOR* SOFOSBUVIR ( SOFALDI – GILEAD )
- PROTEASE INHIBITOR* SIMEPREVIR ( OLYSIO- JANSSEN )
![Page 21: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/21.jpg)
NEW REVOLUTION :
IN FEB. 8TH , 2014 … GILEAD COMPANY
APPLIED FOR FDA APPROVAL OF ONE PREPARATION CONTAINING BOTH
- SOFOSBUVIR + LEDIPASVIR ( COMBO )
TO BE GIVEN IN ONE CAPSULE DAILYFOR 8 WEEKS WITH RESPONSE RATE 95%
-AND IF ADDED RIBA. , RESPONSE RATE 100 %
![Page 22: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/22.jpg)
On the way for FDA Approval, two PIs :
Faldaprivir(Bin) …. Asunaprivir (BMS)
![Page 23: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/23.jpg)
IN 2014 … NEW HCV
DAAs COMBINATION –
INTERFERON-FREE THERAPY
![Page 24: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/24.jpg)
New hepatitis C therapies -
A medical pick And mix
A plethora of direct-acting anti-virals
![Page 25: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/25.jpg)
![Page 26: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/26.jpg)
SUMMARY OF DIRECT-ACTING ANTIVIRALS
Class Drug Dosing
NS3/4A protease inhibitor ABT-450/RTV 150/100 mg
NS3 protease inhibitor Asunaprevir 100 mg BID
NS3/4A protease inhibitor MK-5172 100 mg QD
NS3/4A protease inhibitor Simeprevir 150 mg QD
NS5B nonnucleoside polymerase inhibitor Dasabuvir 250 mg BID
NS5B nucleotide polymerase inhibitor Sofosbuvir 400 mg QD
NS5A inhibitor Daclatasvir 60 mg QD
NS5A inhibitor GS-5816 25 or 100 mg QD
NS5A inhibitor Ledipasvir 90 mg QD
NS5A inhibitor MK-8742 20 or 50 mg QD
NS5A inhibitor Ombitasvir 25 mg QD
![Page 27: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/27.jpg)
(DAAs) for the treatment of hepatitis C are now available and new agents are continually being
added to this list.
To coincide with EASL 2014 in London, UK, the N. E. J. M. has published a series of new HCV therapy
phase III trial results, demonstrating that
We are now truly in the era of interferon- free, All-oral combination therapies for HCV infection.
These DAAs could potentially revolutionize Treatment for HCV , but can we call them
a cure yet?
![Page 28: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/28.jpg)
NEW POLICY IN HCV TREATMENT
ALL IN ONE PILL
![Page 29: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/29.jpg)
The first set of three open-label trials ( All in one Pill )
Examined the use of the HCV NS5A inhibitor Ledipasvir in combination with
Sofosbuvir (an HCV NS5B polymerase inhibitor).
( COMBO ) A number of different patient populations infected with HCV
genotype 1 were studied:
![Page 30: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/30.jpg)
1. HCV-infected patients who were treatment-naive (16% had cirrhosis; 12-week versus 24-
week regimen, with or without ribavirin);
2. Patients with chronic HCV infection without cirrhosis (8-week versus 12-week
treatment regimen, with or without ribavirin);
3. HCV-infected patients who had failed to achieve a sustained virologic response (SVR)
despite treatment with interferon- based therapies (20% had cirrhosis; 12-week versus 24-week regimen, with or without ribavirin).
![Page 31: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/31.jpg)
Patients typically received 90 mg Ledipasvir and 400 mg Sofosbuvir in a combination tablet orally each day; Ribavirin, when
required, was administered at 1,000 mg or 1,200 Mg According to bodyweight.
The studies showed that once-daily ledipasvir– sofosbuvir (with or without
ribavirin) was highly effective (SVRs >90%, with some rates as high as 99%) in HCV- infected patients irrespective of whether
they had received HCV treatment before.
![Page 32: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/32.jpg)
Importantly, the studies found that there
was No additional benefit of including ribavirin within the combination therapy,
Kowdley et al. found no benefit of extension of the treatment period to
12 weeks (8 weeks were sufficient).
![Page 33: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/33.jpg)
The second set of three trials
( AbbVie )
Examined the use of
a three-in-one pill
![Page 34: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/34.jpg)
TRIPLE - INTERFERON FREE -
THERAPY FOR HCV INFECTION
![Page 35: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/35.jpg)
![Page 36: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/36.jpg)
THE COMBINATION OF THREE DIFFERENT MECHANISMS OF ACTION OF THIS 3D COMBINATION
INTERRUPTS THE HCV REPLICATION PROCESS AND OPTIMIZES A SUSTAINED VIROLOGIC
RESPONSE DURING THE 12-WEEK REGIMEN (SVR12) IN HCV PATIENTS.
![Page 37: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/37.jpg)
ABBVIE'S PHASE 2 AVIATOR STUDY COMPARED VARIOUS INTERFERON-FREE THREE- AND FOUR-DRUG COMBINATIONS
CONTAINING:
* THE HCV PROTEASE INHIBITOR ABT-450 BOOSTED WITH RITONAVIR,
* THE HCV NS5A INHIBITOR ABT-267 (OMBITASVIR), * HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR ABT-333
( DASABUVIR )* AND RIBAVIRIN, FOR DURATIONS OF 8, 12 OR 24 WEEKS.
![Page 38: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/38.jpg)
ABBVIE'S PHASE 2 AVIATOR STUDY COMPARED VARIOUS GROUPS AS REPORTED AT EASL 2013, 96% OF TREATMENT-
NAIVE PATIENTS AND 93% OF PRIOR NULL-RESPONDERS WHO RECEIVED ALL FOUR DRUGS FOR 12 WEEKS ACHIEVED
SUSTAINED VIROLOGICAL RESPONSE,
OR CONTINUED UNDETECTABLE HCV RNA, AT 24 WEEKS POST-TREATMENT (SVR24).
THE SUSTAINED RESPONSE RATE WAS LOWER – 87% – FOR PEOPLE TAKING THE THREE DIRECT-ACTING ANTIVIRALS
WITHOUT RIBAVIRIN FOR 12 WEEKS
![Page 39: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/39.jpg)
![Page 40: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/40.jpg)
![Page 41: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/41.jpg)
![Page 42: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/42.jpg)
![Page 43: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/43.jpg)
![Page 44: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/44.jpg)
![Page 45: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/45.jpg)
![Page 46: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/46.jpg)
THIRD STUDY : A COMBINATION OF TWO DAAA DACLATASVIR & ASUNAPREVIR DEVELOPED BY BMS CURED 90% OF PREVIOUSLY UNTREATED PEOPLE WITH G 1B IN 24 WEEKS, WITHOUT THE NEED FOR PEGYLATED INTERFERON OR RIBAVIRIN.( MANNS, 49TH ANNUAL MEETING OF EASL IN UK, 2014)
THE INTERFERON- AND RIBAVIRIN-FREE REGIMEN COMBINED THE NS5A INHIBITOR DACLATASVIR AND THE PROTEASE INHIBITOR ASUNAPREVIR.
THE TWO DRUGS ARE ALSO BEING TESTED ALONGSIDE A THIRD AGENT, THE NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR BMS-791325, IN TWO PHASE III STUDIES ( TRIPLE THERAPY )
![Page 47: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/47.jpg)
IN EUROPE, BMS IS PURSUING AN EARLY APPROVAL FOR DACLATASVIR AS AN INDIVIDUAL AGENT, SO THAT IT MAY BE USED IN COMBINATION WITH SOFOSBUVIR FOR TREATMENT OF GENOTYPES 1, 3 AND 4 OR IN COMBINATION WITH PEGYLATED INTERFERON AND RIBAVIRIN FOR TREATMENT OF GENOTYPES 1B AND 4, AS RECOMMENDED IN NEW EASL GUIDELINES, 2014.
![Page 48: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/48.jpg)
QUADRUPLE THERAPIES (THERAPY WITH FOUR DRUGS)
PEOPLE WITH VIRUS WHICH HAS PREVIOUSLY PROVED VERY DIFFICULT TO TREAT (E.G. NON-RESPONDERS AND NULL-
RESPONDERS), COULD BENEFIT FROM THE COMBINATION OF :
PEGINTERFERON AND RIBAVIRIN WITH
TWO ANTIVIRAL ACTIVE SUBSTANCES. IT MAY ALSO BE POSSIBLE TO SHORTEN THE OVERALL
THERAPY PERIOD, ALTHOUGH EVEN MORE SERIOUS SIDE-EFFECTS MAY HAVE TO BE TAKEN INTO ACCOUNT .
![Page 49: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/49.jpg)
“We can say that we now have a cure for hepatitis C, which is particularly
true for treatment-naive patients without advanced cirrhosis.
” Michael Manns, EASL 2014 ”
![Page 50: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/50.jpg)
However, as hepatitis C treatment rapidly evolves, Manns acknowledges that :
Clinicians are currently working with a “moving target” when it comes to how best to treat their patients as new drugs and new
drug combinations emerge.
It is not just a question of which drug to use,
but which combination of drugs to choose !!
![Page 51: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/51.jpg)
Despite their success, a major issue of concern with these new DAAs has been
their expense, as well as regulatory issues across different countries.
Hopefully, over the coming years, these therapies will follow the lead of the HIV field and substantially reduce in cost ,
![Page 52: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/52.jpg)
Several major challenges do remain before we can truly move towards the global eradication of HCV infection,
Particularly access to new DAAs in low- income and middle-income countries and
effective HCV screening programmes .
(Too often diagnosis still comes at a late stage).
![Page 53: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/53.jpg)
Moreover, more attention needs to be focused on special patient
populations.
“We still have yet to explore treatments in patients with
Decompensated Cirrhosis,
” Manns explains, “which is a major task” .
![Page 54: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/54.jpg)
SOFOSBUVIR + RIBAVIRIN IS SAFE AND EFFECTIVE FOR PEOPLE WITH HCV WHO HAVE ADVANCED LIVER DISEASE
(LIZ HIGHLEYMAN / 17 APRIL 2014 )
SOFOSBUVIR PLUS RIBAVIRIN IS A SAFE OPTION THAT CAN LEAD TO SUSTAINED RESPONSE IN
PEOPLE WITH ADVANCED LIVER DISEASE INCLUDING THOSE WITH DECOMPENSATED CIRRHOSIS AND
PORTAL HYPERTENSION, AND PEOPLE WHO EXPERIENCE SEVERE HEPATITIS
Q : ( GENOTYPE IV - NON-RESPONDERS, BREAK-THROUGH- RELAPSERS ? )
![Page 55: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/55.jpg)
NHS ENGLAND AGREES FUNDING
FOR LIFE-SAVING HEPATITIS C DRUG( SOFOBUVIR- SOFALDI )
16 APRIL 2014 - 17:37
![Page 56: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/56.jpg)
THE RECOMMENDATION OF NHS ENGLAND’S CLINICAL PRIORITIES ADVISORY GROUP (CPAG)
MEANS THAT WHILST NOT YET NICE-APPROVED, SOFOSBUVIR WILL BE FUNDED FOR :
THOSE PATIENTS AT SIGNIFICANT RISK OF MORTALITY OR WHO REQUIRE TRANSPLANTATION.
![Page 57: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/57.jpg)
EASL HCV GUIDELINES 2014: GENOTYPE 1
Genotype Options for Therapy
Genotype 1*
PegIFN/ribavirin + sofosbuvir: 12 wks (A1)
PegIFN/ribavirin + simeprevir†: 12 wks, followed by 12 wks of pegIFN/ribavirin in previously untreated pts and prior relapsers (A1), or 36 wks of pegIFN/ribavirin in previous partial responders and null responders (B1)
PegIFN/ribavirin + daclatasvir (genotype 1b only; B1): 12 wks followed by 12 wks of pegIFN/ribavirin alone or a further 12 wks of pegIFN/ribavirin + daclatasvir (response-guided therapy) (B2)
Sofosbuvir + ribavirin: 24 wks for interferon-intolerant pts only, where no other interferon-free option available (B2)
Sofosbuvir + simeprevir: 12 wks (ribavirin may be added for previous nonresponders & cirrhotics) (B1)
Sofosbuvir + daclatasvir: 12 wks in previously untreated pts; 24 wks in treatment-experienced patients (including TVR/BOC-experienced patients) (ribavirin may be added in previous nonresponders and cirrhotics) (B1)
EASL. J Hepatology. 2014;60:392-420.
*In settings where recommended options are not available, treatment with pegIFN/ribavirin + TVR or BOC remains acceptable. †Not recommended in pts with genotype 1a and detectable Q80K polymorphism.
![Page 58: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/58.jpg)
EASL HCV GUIDELINES 2014: GENOTYPE 2-6Genotype Options for Therapy
Genotype 2*
Sofosbuvir + ribavirin: 12 wks (16-20 weeks in cirrhotic patients, especially treatment experienced) (A1)
PegIFN/ribavirin + sofosbuvir: 12 wks for cirrhotic and/or treatment-experienced patients (B1)
Genotype 3*
Sofosbuvir + ribavirin: 24 wks (unsuitable for treatment-experienced cirrhotics, no specific alternative proposed) (A2)
PegIFN/ribavirin + sofosbuvir: 12 wks (A2)
Sofosbuvir + daclatasvir: 12 wks (24 wks for treatment-experienced patients) (B1)
Genotype 4*
PegIFN/ribavirin + sofosbuvir 12 weeks (B1)
PegIFN/ribavirin + simeprevir: 12 wks, followed by 12 wks of pegIFN/ribavirin in previously untreated patients & prior relapsers (B1), or 36 wks of pegIFN/ribavirin in previous partial responders & null responders (B1)
PegIFN/ribavirin + daclatasvir: 12 wks followed by 12 wks of pegIFN/ribavirin alone or a further 12 wks of pegIFN/ribavirin + daclatasvir (response-guided therapy) (B1)
Sofosbuvir + ribavirin: 24 wks for interferon-intolerant patients (C2)
Sofosbuvir + simeprevir: 12 wks (ribavirin may be added in previous nonresponders and cirrhotics) (B2)
Sofosbuvir + daclatasvir: 12 wks in previously untreated patients; 24 wks in treatment-experienced patients (ribavirin may be added in previous nonresponders and cirrhotics) (B2)
Genotype 5/6*
PegIFN/ribavirin + sofosbuvir 12 wks (B1)
Sofosbuvir + ribavirin: 24 wks for interferon-intolerant patients (C2)
EASL. J Hepatology. 2014;60:392-420.
*In settings where recommended options are not available, treatment with pegIFN/ribavirin remains acceptable.
![Page 59: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/59.jpg)
WHO HCV GUIDELINES 2014: RECOMMENDATIONS ON HCV TREATMENT
• All adults and children with chronic HCV infection, including people who inject drugs, should be assessed for antiviral treatment (strong recommendation; moderate quality of evidence)
• PegIFN + RBV recommended rather than standard nonpegylated IFN with RBV (strong recommendation; moderate quality of evidence)
• TVR or BOC, in combination with pegIFN/RBV, suggested for GT1 chronic HCV infection rather than pegIFN/RBV alone (conditional recommendation; moderate quality of evidence)
• Sofosbuvir, in combination with RBV with or without pegIFN (depending on HCV genotype), recommended for GT1-4 HCV infection rather than pegIFN/RBV alone (and rather than no treatment for persons who cannot tolerate IFN) (strong recommendation; high quality of evidence)
• Simeprevir, in combination with pegIFN/RBV, recommended for GT1b HCV infection and genotype 1a HCV infection without the Q80K polymorphism, rather than pegIFN/RBV alone (strong recommendation; high quality of evidence)
WHO 2014. Guidelines for the screening, care and treatment of persons with hepatitis C infection.
![Page 60: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/60.jpg)
So , do we still need to have a Whiff of Interferon at
the beginning of therapy with DAAs to boost the
host immune system and this may Decrease the
relapse rate, break-though and resistance
( <<<<< We need more studies >>>>>)
![Page 61: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/61.jpg)
PROS AND CONS OF
NEW DAAS
![Page 62: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/62.jpg)
HCV variants that are resistant to DAAs emerge in patients who experience
virologic failure.
Multiclass resistance emerges in patients on interferon alfa- free regimens that
contain DAAs, with the possible exception of resistance to nucleoside pol. inhibitors.
.
![Page 63: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/63.jpg)
The long-term impact of emergence of resistant variants is not known at this point.
It is known that such variants decay over time, but it remains unclear whether re-exposure to the same drug classes will
result in rapid re-emergence of resistance.
.
![Page 64: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/64.jpg)
Progress in devising interferon alfa-free regimens is rapid and can be expected to
continue in this manner for the next several years.
Hope remains that interferon- free regimens can be crafted for the vast majority of HCV
patients within the near future….THEN WHAT?
![Page 65: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/65.jpg)
So , what do we need in Egypt ?And we have to wait for What ?
* The most effective combinations .
* The least side effects.
* The least resistance, break through and relapse .
•The most economic preparations . ( So , Pick and Mix Policy – Manns, 2014 )
![Page 66: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/66.jpg)
We have to keep also in mind that ::
Eradication of HCV infection in one person
Eradicating a source of infection
The best way of HCV Prevention
And approaching the end of HCV Epidemic
![Page 67: Pros and cons of new hcv ttt](https://reader038.vdocument.in/reader038/viewer/2022110302/54780d21b4af9fde588b461a/html5/thumbnails/67.jpg)
THANK YOUTHANK YOU